Oral D-Amphetamine Causes Prolonged Displacement of [ 11C]Raclopride as Measured by PET

Synapse

Volumn 51, Issue 1, 2004, Pages 27-31

  Cárdenas, Laura ^a,c   Houle, Sylvain ^b,c   Kapur, Shitij ^b,c   Busto, Usoa E ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

D amphetamine; Dopamine; Dopamine D2 receptors; Positron emission tomography

Indexed keywords

DEXAMPHETAMINE; DOPAMINE; DOPAMINE 2 RECEPTOR; RACLOPRIDE;

ADULT; ARTICLE; BINDING KINETICS; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; FEMALE; HUMAN; HUMAN EXPERIMENT; INTERNALIZATION; ISOTOPE LABELING; MALE; NEUROMODULATION; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR BINDING; SYNAPTIC TRANSMISSION;

ADMINISTRATION, ORAL; ADULT; CARBON RADIOISOTOPES; DEXTROAMPHETAMINE; FEMALE; HUMANS; MALE; MIDDLE AGED; PROTEIN BINDING; RACLOPRIDE; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0242664957     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/syn.10282     Document Type: Article

References (19)

1. Breier A, Su T-P, Saunders R, Carson R, Kolachana B, De Bartolomeis A, Weinberger D, Weisenfeld N, Malhotra A, Eckelman W, Pickar D. 1997. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA 94:2569-2574.
2. Borcherding B, Keysor C, Cooper T, Rapoport J. 1989. Differential effects of methylphenidate and dextroamphetamine on the motor activity level of hyperactive children. Neuropsychopharmacology 2:255-263.
3. Cardenas L, Tremblay L, Naranjo C, Herrmann N, Zack M, Busto U. 2002. Brain reward system activity in major depression and comorbid nicotine dependence. J Pharmacol Exp Ther 302:1265-1271.
4. 11C]raclopride in anesthetized monkeys. In: Gjedde A, Hansen S, Knudsen G, Paulson O, editors. Physiological imaging of the brain with PET. San Diego: Academic Press. p 205-209.
5. Cyr M, Brown C. 1998. Current drug therapy recommendations for the treatment of attention deficit hyperactivity disorder. Drugs 55:215-223.
6. De Wit H, Uhlenhuth E, Johanson C. 1987. The reinforcing properties of amphetamine in overweight subjects and subjects with depression. Clin Pharmacol Ther 42:127-136.
7. Dewey S, Smith G, Logan J, Brodie J, Fowler J, Wolf A. 1993. Striatal binding of the PET ligand 11C-raclopride is altered by drugs that modify synaptic dopamine levels. Synapse 13:350-356.
8. 11C]raclopride binding to D2-dopamine receptors studied by PET - a comparison to the equilibrium analysis. J Cereb Blood Flow Metab 9:696-708.
9. 11C]raclopride in man. Synapse 20:200-208.
10. 11C]raclopride in anaesthestised rodents. Neuroimage 3:S11.
11. 2 receptor in nonhuman primates. Synapse 10:177-184.
12. Lammertsma A, Hume S. 1996. Simplified reference tissue model for PET receptor studies. Neuroimage 4:153-158.
13. Laruelle M. 2000. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab 20:423-451.
14. Laruelle M, Iyer R, Al-Tikriti M, Zea-Ponce Y, Malison R, Zoghbi S, Baldwin R, Kung H, Charney D, Hoffer P, Innis R, Bradberry C. 1997. Microdialysis and SPECT measurements of amphetamine-induced dopamine release in nonhuman primates. Synapse 25:1-14.
15. 11C]raclopride study in healthy men. Neuropsychopharmacology 27:1027-1035.
16. 11C]raclopride at dopamine receptors in human subjects. Am J Psychiatry 154:1209-1213.
17. 3H]raclopride: implications for positron emission tomography of the human brain. Synapse 3:96-97.
18. Tremblay L, Naranjo C, Cardenas L, Herrmann N, Busto U. 2002. Probing brain reward system function in major depressive disorder: altered response to dextroamphetamine. Arch Gen Psychiatry 59:409-416.
19. 2 receptors. J Comput Assist Tomogr 20:423-428.